Literature DB >> 17531952

Thermodynamics imprinting reveals differential binding of metals to alpha-synuclein: relevance to Parkinson's disease.

K S J Rao.   

Abstract

The aggregation of alpha-synuclein is a hallmark feature of Parkinson's disease (PD) and other synucleinopathies. Metals are the significant etiological factors in PD, and their interaction with alpha-synuclein affect dramatically the kinetics of fibrillation in vitro and are proposed to play an important and potential neurodegenerative role in vivo. In the present study, we investigated the stoichiometry of binding of copper [Cu (II)] and iron [Fe (III)] with alpha-synuclein (wild recombinant type and A30P, A53T, E46K mutant forms) using isothermal titration calorimetry (ITC). alpha-Synuclein monomer (wild and mutant forms) titrated by Cu (II), showed two binding sites, with an apparent K(B) of 10(5)M and 10(4)M, respectively. But, alpha-synuclein (wild type and mutant forms) titrated with Fe (III) revealed a K(B) of 10(5)M with single binding site. The present investigation uncovers the detailed binding propensities between metals and alpha-synuclein and has biological implications in PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531952     DOI: 10.1016/j.bbrc.2007.05.060

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  α-Synuclein Over-Expression Induces Increased Iron Accumulation and Redistribution in Iron-Exposed Neurons.

Authors:  Richard Ortega; Asuncion Carmona; Stéphane Roudeau; Laura Perrin; Tanja Dučić; Eleonora Carboni; Sylvain Bohic; Peter Cloetens; Paul Lingor
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

Review 2.  Interaction between alpha-synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson's disease.

Authors:  Marco Bisaglia; Isabella Tessari; Stefano Mammi; Luigi Bubacco
Journal:  Neuromolecular Med       Date:  2009       Impact factor: 3.843

3.  Chromatin-Bound Oxidized α-Synuclein Causes Strand Breaks in Neuronal Genomes in in vitro Models of Parkinson's Disease.

Authors:  Velmarini Vasquez; Joy Mitra; Pavana M Hegde; Arvind Pandey; Shiladitya Sengupta; Sankar Mitra; K S Rao; Muralidhar L Hegde
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

4.  Specific Inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential etiological linkage to neurodegenerative diseases.

Authors:  Muralidhar L Hegde; Pavana M Hegde; Luis M F Holthauzen; Tapas K Hazra; K S Jagannatha Rao; Sankar Mitra
Journal:  J Biol Chem       Date:  2010-07-09       Impact factor: 5.157

5.  Comparison of the structural characteristics of Cu(2+)-bound and unbound α-syn12 peptide obtained in simulations using different force fields.

Authors:  Zanxia Cao; Lei Liu; Liling Zhao; Haiyan Li; Jihua Wang
Journal:  J Mol Model       Date:  2012-11-18       Impact factor: 1.810

Review 6.  α-Synuclein Misfolding Versus Aggregation Relevance to Parkinson's Disease: Critical Assessment and Modeling.

Authors:  Ruben Berrocal; Velmarini Vasquez; Sambasiva Rao Krs; Bharathi S Gadad; K S Rao
Journal:  Mol Neurobiol       Date:  2014-08-20       Impact factor: 5.590

7.  Molecular understanding of copper and iron interaction with alpha-synuclein by fluorescence analysis.

Authors:  K S J Rao
Journal:  J Mol Neurosci       Date:  2008-05-20       Impact factor: 3.444

8.  Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping.

Authors:  Naying He; Huawei Ling; Bei Ding; Juan Huang; Yong Zhang; Zhongping Zhang; Chunlei Liu; Kemin Chen; Fuhua Yan
Journal:  Hum Brain Mapp       Date:  2015-08-07       Impact factor: 5.038

9.  Alpha-synuclein is a cellular ferrireductase.

Authors:  Paul Davies; Dima Moualla; David R Brown
Journal:  PLoS One       Date:  2011-01-10       Impact factor: 3.240

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.